Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing and marketing Indian Formulations, International Generics, and Active Pharmaceutical ...

Alembic Limited is an India-based company engaged in the business of development, manufacturing, and marketing of pharmaceutical products. The Company's segments include the Active Pharmaceutical ...

The average daily trading volume for Alembic Pharmaceuticals Ltd (ALEM) is 174,296. How Many Times Has Alembic Pharmaceuticals Ltd Stock Split? Alembic Pharmaceuticals Ltd has split 0 times. What Is ...

The Alembic Pharmaceuticals Ltd dividend yield is 1.49. What Is The Ex-Dividend Date For Alembic Pharmaceuticals Ltd? The next ex-dividend date for Alembic Pharmaceuticals Ltd is Jul 29, 2026. Alembic ...

Aug 27, 2026, 9:59 PM IST Alembic Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Aug 27, 2026, 9:57 PM IST Alembic Pharma. - Announcement under Regulation 30 ...

Aug 27, 2026, 09:59 PM IST IST Alembic Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Aug 27, 2026, 09:57 PM IST IST Alembic Pharma. - Announcement under ...

Alembic Pharmaceuticals Limited is a leading research-driven, integrated pharmaceutical enterprise specialising in the development and manufacturing of generic formulations across diverse therapeutic ...

As a staff writer for Forbes Advisor, SMB, Kristy helps small business owners find the tools they need to keep their businesses running. She uses the experience of managing her own writing and editing ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Track the company's earnings performance through key income statement metrics such as revenue, net profit, and operating income. Analyse trends in income growth, expenses, profitability, and earnings ...

The pharma business also announced that it has already secured final USFDA approvals for Bosutinib Tablets in the 100 mg and 500 mg strengths.

Package Version: 0.0.1 A2A SDK: v1.0.2 (a2a-sdk[http-server]) Status: Phases 1–13 implemented; Phase 10 bridges (Hermes, Core Engine, OpenClaw) operational; Phase 12 conversation grouping via ...